{"id":89441,"date":"2026-05-12T22:28:33","date_gmt":"2026-05-13T04:28:33","guid":{"rendered":"https:\/\/trimrx.com\/blog\/?p=89441"},"modified":"2026-05-13T16:47:17","modified_gmt":"2026-05-13T22:47:17","slug":"does-semaglutide-cause-cancer-2026","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/does-semaglutide-cause-cancer-2026\/","title":{"rendered":"Does Semaglutide Cause Cancer: 2026 Research Update"},"content":{"rendered":"

Introduction<\/h2>\n

The current state of evidence as of 2026: no human data has linked semaglutide to increased cancer risk, and some studies show reduced rates of obesity-related cancers in users. The boxed warning for medullary thyroid carcinoma remains in place because of rodent C-cell tumor findings, not human evidence.<\/p>\n

The SELECT cardiovascular outcomes trial (Lincoff et al. 2023 NEJM) followed 17,604 patients on semaglutide for up to 4 years and found no excess cancer signal. The 2024 JAMA Otolaryngology analysis of 350,000+ GLP-1 users found no increased thyroid cancer rate. The 2024 JAMA Network Open study on obesity-associated cancers showed GLP-1 receptor agonists associated with lower rates of 10 of 13 obesity-linked cancer types compared with insulin.<\/p>\n

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n

What Does the FDA Warning on Semaglutide Actually Mean?<\/h2>\n

Semaglutide (Wegovy\u00ae and Ozempic\u00ae) carries a boxed warning prohibiting use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).<\/strong> The basis is 2-year rodent carcinogenicity studies where rats developed thyroid C-cell tumors at clinically relevant exposures.<\/p>\n

Quick Answer: FDA boxed warning is based on rat thyroid C-cell tumors, not human data<\/p>\n

The same warning appears on every GLP-1 receptor agonist on the market. It’s a class effect of the rodent toxicology profile, not a confirmed human risk. Whether the rat data translates to humans is the unresolved scientific question.<\/p>\n

What the warning does do well: it correctly excludes the small population of patients who have abnormal proliferating C-cells (MTC or MEN2) and shouldn’t have GLP-1 receptors stimulated for any reason.<\/p>\n

Has Semaglutide Caused Cancer in Humans?<\/h2>\n

No confirmed causation in published research as of 2026.<\/strong> The SELECT trial (Lincoff et al. 2023 NEJM) is the largest randomized data: 17,604 adults with obesity and cardiovascular disease, followed up to 4 years on semaglutide 2.4 mg or placebo. Cancer rates were similar between arms.<\/p>\n

The SUSTAIN cardiovascular outcomes program (SUSTAIN-6, Marso et al. 2016 NEJM) also showed no cancer signal at 2-year follow-up. The STEP 1 through STEP 5 weight-management trials (collectively several thousand patients over 1 to 2 years) showed no excess cancer.<\/p>\n

Observational data is even larger. A 2024 JAMA Otolaryngology study by Bea-Mascato et al. on 350,000+ GLP-1 users found no thyroid cancer increase. A 2024 JAMA Network Open study by Wang et al. on 1.6 million patients with obesity-associated cancers found GLP-1 RAs associated with lower rates of 10 of 13 cancer types compared with insulin.<\/p>\n

Is Semaglutide Associated with Pancreatic Cancer?<\/h2>\n

The pancreatic cancer signal is older, weaker, and not confirmed.<\/strong> A 2013 paper raised concerns based on autopsy findings, which were subsequently challenged and not replicated. A 2017 BMJ meta-analysis by Pinto et al. of 35 trials found no pancreatic cancer signal for incretin therapies.<\/p>\n

The SELECT trial showed no increase in pancreatic cancer. The STEP and SUSTAIN trial programs combined have not produced a confirmed pancreatic cancer signal. The 2024 observational analyses show no excess risk.<\/p>\n

What semaglutide does carry is a real but low-frequency risk of acute pancreatitis (inflammation, not cancer). Pancreatitis hasn’t translated into elevated cancer rates on follow-up.<\/p>\n

What About Thyroid Cancer Specifically?<\/h2>\n

The 2023 BMJ study by Bezin et al.<\/strong> using French claims data initially reported a small increased thyroid cancer risk with GLP-1 use (hazard ratio around 1.5). This got widespread media coverage. A 2024 reanalysis in JAMA Internal Medicine by Hicks et al. with better matching and longer follow-up did not replicate the finding.<\/p>\n

The 2024 JAMA Otolaryngology study (Bea-Mascato et al.) used different and larger U.S. data and found no thyroid cancer signal, including for medullary thyroid carcinoma specifically. The current consensus from multiple analyses is that the initial French signal didn’t hold up.<\/p>\n

Thyroid cancer incidence has been climbing globally for decades because of improved imaging detecting small papillary cancers. This trend predates GLP-1 drugs and isn’t attributable to them.<\/p>\n

Could Semaglutide Actually Reduce Cancer Risk?<\/h2>\n

There’s growing evidence pointing in this direction.<\/strong> Obesity is an established risk factor for 13 cancers per the International Agency for Research on Cancer, including breast, colorectal, endometrial, esophageal, kidney, liver, pancreatic, gastric, ovarian, multiple myeloma, meningioma, thyroid, and gallbladder.<\/p>\n

A 2024 JAMA Network Open study by Wang et al. compared cancer rates in patients on GLP-1 receptor agonists versus insulin (matched on diabetes severity) over 15 years of follow-up. GLP-1 users had lower rates of 10 of 13 obesity-related cancers.<\/p>\n

The mechanism is plausible: reducing obesity reduces chronic inflammation, insulin resistance, and adipokine signaling that drive cancer biology. A 2023 study in Cell Metabolism (Drucker) reviewed the broader anti-inflammatory effects of GLP-1 receptor agonists beyond glycemic control.<\/p>\n

This isn’t definitive proof semaglutide prevents cancer. But it pushes back against the framing that semaglutide causes cancer.<\/p>\n

What Kind of Long-term Data Do We Have?<\/h2>\n

Liraglutide (Victoza\u00ae) has been on the market since 2010, semaglutide (Ozempic) since 2017, Wegovy since 2021.<\/strong> The longest follow-up cohorts cover 10 to 15 years for liraglutide and 5 to 7 years for semaglutide.<\/p>\n

The SELECT trial provides the largest randomized follow-up at 4 years. The LEADER trial with liraglutide (Marso et al. 2016 NEJM) provides 4 years of randomized cardiovascular outcomes data with no cancer signal.<\/p>\n

Observational databases now cover tens of millions of patient-years. Surveillance through FDA Adverse Event Reporting, the European Medicines Agency pharmacovigilance system, and major claims databases continues.<\/p>\n

A signal hasn’t emerged. If one exists at the level of clinical concern, it should have shown up by now.<\/p>\n

Key Takeaway: Emerging evidence suggests reduced obesity-related cancer risk on semaglutide<\/p>\n

Who Absolutely Shouldn’t Take Semaglutide Because of Cancer Risk?<\/h2>\n

Personal or family history of medullary thyroid carcinoma.<\/strong> Personal or family history of multiple endocrine neoplasia syndrome type 2 (MEN2A or MEN2B). Known RET proto-oncogene mutations.<\/p>\n

These patients have abnormal, proliferating thyroid C-cells. Stimulating GLP-1 receptors on those cells is a real concern regardless of whether the general-population rodent finding translates.<\/p>\n

For patients with other cancer histories, decisions are individualized. Active cancer treatment usually warrants discussion with oncology before starting or continuing semaglutide. Cancer survivors in remission can typically use semaglutide if otherwise appropriate.<\/p>\n

Should I Get Cancer Screening Before Semaglutide?<\/h2>\n

No special pre-treatment cancer screening is recommended beyond standard age-appropriate screening (colonoscopy at 45+, mammography per guidelines, etc.).<\/strong> Routine thyroid ultrasound or calcitonin testing isn’t recommended for low-risk patients.<\/p>\n

If you have family history of MTC or MEN2, you shouldn’t be on semaglutide anyway. If you have a personal cancer history, talk to your oncologist before starting.<\/p>\n

Through TrimRx, the free assessment quiz screens for MTC and MEN2 contraindications. If you’re cleared on those and don’t have active cancer, the personalized treatment plan can include compounded semaglutide.<\/p>\n

How Does Semaglutide Cancer Risk Compare to Obesity Cancer Risk?<\/h2>\n

Obesity contributes to roughly 4 to 8% of all cancers globally per a 2016 NEJM analysis.<\/strong> Treating obesity meaningfully reduces these obesity-related cancer risks.<\/p>\n

So the relevant comparison isn’t “does semaglutide cause cancer” in a vacuum. It’s “does the theoretical, unconfirmed thyroid C-cell risk outweigh the substantial obesity-related cancer risk reduction.” Current evidence says no, the trade-off favors treatment for patients without MTC or MEN2 history.<\/p>\n

A patient with obesity who avoids semaglutide because of cancer fear is choosing a confirmed cancer risk (obesity-related) over a theoretical and unconfirmed one (thyroid C-cell).<\/p>\n

What’s the Latest 2026 Research on Semaglutide and Cancer?<\/h2>\n

The SELECT extension data, the FLOW trial follow-up (Perkovic et al.<\/strong> 2024 NEJM, primary outcome was kidney\/CV death), and ongoing post-marketing surveillance have continued to show no excess cancer signal. New 2025 and early 2026 publications have largely focused on potentially protective effects, particularly for obesity-related cancers.<\/p>\n

The MAESTRO-NASH trial extensions and the ESSENCE phase 3 semaglutide for MASH program have produced incidental cancer rate data, again showing no excess signal.<\/p>\n

Several ongoing prospective registries (CaTHCAS in Scandinavia, the FDA-mandated post-marketing studies in the U.S.) will produce additional definitive data over the next 5 to 10 years.<\/p>\n

Bottom line: Long-term surveillance past 5 to 10 years continues to accumulate<\/p>\n

FAQ<\/h2>\n

Does Semaglutide Cause Breast Cancer?<\/h3>\n

No evidence supports this. The 2024 JAMA Network Open study found GLP-1 RAs associated with lower breast cancer rates compared with insulin in obesity-related cancer analysis.<\/p>\n

Can Semaglutide Cause Colon Cancer?<\/h3>\n

No data shows an increase. Some evidence suggests lower colorectal cancer rates in GLP-1 users with obesity, consistent with the obesity-cancer link reduction.<\/p>\n

Should I Stop Semaglutide If I’m Diagnosed with Cancer?<\/h3>\n

Decide with your oncologist based on cancer type and treatment plan. For most non-thyroid cancers, semaglutide isn’t automatically contraindicated.<\/p>\n

Is Compounded Semaglutide Cancer Risk Different From Ozempic?<\/h3>\n

Same molecule, same theoretical risk. The compounded product doesn’t have a separate boxed warning because of compounding pharmacy rules, but the biology is identical.<\/p>\n

How Long Until We Definitively Know If Semaglutide Causes Cancer?<\/h3>\n

Likely 10 to 15 more years of post-marketing data. Current 5 to 7 year cohorts are reassuring but not conclusive for very long-term effects.<\/p>\n

Will My Insurance Cover Thyroid Screening Before Semaglutide?<\/h3>\n

Probably not for routine screening. Insurance typically only covers screening if there’s a specific indication like family history or symptoms.<\/p>\n

Should I Be Worried About Cancer If I’ve Been on Ozempic for Years?<\/h3>\n

If you have no family history of MTC or MEN2, current data is reassuring. Continue normal age-appropriate cancer screening. The hypothetical thyroid risk hasn’t materialized in human data through 15 years of GLP-1 receptor agonist use.<\/p>\n

Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n

<\/p>\n

Related Articles<\/h2>\n